Phase III trial of ipilimumab in metastatic melanoma demonstrates improvement in survival

被引：0
|
作者：
不详
机构：
来源：
FUTURE ONCOLOGY | 2010年 / 6卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1208 / 1208
页数：1
相关论文
共 50 条
  • [1] Phase III trial of ipilimumab in metastatic melanoma demonstrates improvement in survival
    不详
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (08) : 1168 - 1168
  • [2] Ipilimumab Ups Survival in Metastatic Melanoma Phase III Trial
    不详
    ONCOLOGY-NEW YORK, 2010, 24 (07): : 648 - 648
  • [3] Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma
    Weber, J. S.
    Muramatsu, T.
    Hamid, O.
    Mehnert, J.
    Hodi, F. S.
    Krishnarajapet, S.
    Malatyali, S.
    Buchbinder, E.
    Goldberg, J.
    Sullivan, R.
    Faries, M.
    Mehmi, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S869 - S869
  • [4] Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma
    Maio, M.
    Bondarenko, I.
    Robert, C.
    Thomas, L.
    Garbe, C.
    Testori, A.
    Lu, H.
    Chin, K.
    Wolchok, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S857 - S857
  • [5] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
    Hodi, F. Stephen
    O'Day, Steven J.
    McDermott, David F.
    Weber, Robert W.
    Sosman, Jeffrey A.
    Haanen, John B.
    Gonzalez, Rene
    Robert, Caroline
    Schadendorf, Dirk
    Hassel, Jessica C.
    Akerley, Wallace
    van den Eertwegh, Alfons J. M.
    Lutzky, Jose
    Lorigan, Paul
    Vaubel, Julia M.
    Linette, Gerald P.
    Hogg, David
    Ottensmeier, Christian H.
    Lebbe, Celeste
    Peschel, Christian
    Quirt, Ian
    Clark, Joseph I.
    Wolchok, Jedd D.
    Weber, Jeffrey S.
    Tian, Jason
    Yellin, Michael J.
    Nichol, Geoffrey M.
    Hoos, Axel
    Urba, Walter J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08): : 711 - 723
  • [6] Ipilimumab improves survival in metastatic melanoma patients
    Hodi, F. S.
    O'Day, S. J.
    McDermott, D. F.
    IMMUNOTHERAPY, 2011, 3 (08) : 928 - 929
  • [7] PREDICTORS OF SURVIVAL FOR THERAPY WITH IPILIMUMAB IN METASTATIC MELANOMA
    Valpione, S.
    Bazzi, M.
    Piccin, L.
    Pigozzo, J.
    Chiarion-Sileni, V.
    ANNALS OF ONCOLOGY, 2014, 25
  • [8] Ipilimumab: showing survival benefit in metastatic melanoma
    Minchom, Anna
    Young, Kate
    Larkin, James
    FUTURE ONCOLOGY, 2011, 7 (11) : 1255 - 1264
  • [9] Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
    Schadendorf, Dirk
    Hodi, F. Stephen
    Robert, Caroline
    Weber, Jeffrey S.
    Margolin, Kim
    Hamid, Omid
    Patt, Debra
    Chen, Tai-Tsang
    Berman, David M.
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1889 - U48
  • [10] Enrollment completed for phase III trial in advanced metastatic melanoma
    不详
    ONCOLOGY-NEW YORK, 2004, 18 (02): : 167 - 168
12345